New Gene Therapy Can Restore Hearing in Deaf Kids
Digest more
Astellas Pharma has done some spring cleaning of its pipeline, dropping two phase 1 candidates and slamming the brakes on a ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard, will present ...
Learn about the groundbreaking gene therapy for sickle cell disease at Manning Family Children's Hospital in Louisiana, ...
AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one-time gene silencing in the central nervous system AviadoBio will present k ...
Dyno Therapeutics to present new capsids and AI advancements in gene delivery at the 29th American Society of Gene & Cell Therapy Annual Meeting ...
Gene editing has emerged as a powerful approach for targeting the genetic causes of disease, but getting the editing ...
In vitro data demonstratedself-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to ...
Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results